NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
0.9282
Dollar change
+0.0982
Percentage change
11.83
%
Index- P/E- EPS (ttm)-5.38 Insider Own47.75% Shs Outstand5.19M Perf Week7.31%
Market Cap5.63M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.91M Perf Month-9.88%
Enterprise Value2.06M PEG- EPS next Q- Inst Own0.51% Short Float1.32% Perf Quarter-9.88%
Income-15.48M P/S- EPS this Y- Inst Trans-8.39% Short Ratio0.29 Perf Half Y-67.99%
Sales0.00M P/B0.62 EPS next Y- ROA-98.96% Short Interest0.04M Perf YTD-49.00%
Book/sh1.49 P/C1.51 EPS next 5Y- ROE-221.23% 52W High17.75 -94.77% Perf Year-39.33%
Cash/sh0.61 P/FCF- EPS past 3/5Y60.23% 55.37% ROIC-200.79% 52W Low0.66 41.11% Perf 3Y-99.72%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility12.67% 8.11% Perf 5Y-99.98%
Dividend TTM- EV/Sales- EPS Y/Y TTM87.16% Oper. Margin- ATR (14)0.09 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.02 Sales Y/Y TTM- Profit Margin- RSI (14)46.52 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio1.02 EPS Q/Q60.05% SMA20-3.36% Beta0.24 Target Price1520.00
Payout- Debt/Eq0.02 Sales Q/Q- SMA50-7.93% Rel Volume0.34 Prev Close0.83
Employees3 LT Debt/Eq0.00 Earnings- SMA200-44.30% Avg Volume134.34K Price0.93
IPOJun 27, 2017 Option/ShortNo / Yes EPS/Sales Surpr.84.62% - Trades Volume46,432 Change11.83%
Date Action Analyst Rating Change Price Target Change
Sep-15-21Initiated Maxim Group Buy $11
May-01-25 09:30AM
Apr-30-25 08:30AM
Dec-27-24 09:00AM
Dec-12-24 08:00AM
Dec-04-24 08:00AM
08:00AM Loading…
Oct-31-24 08:00AM
Oct-29-24 08:00AM
Oct-25-24 09:00AM
Oct-17-24 10:52AM
Oct-16-24 08:00AM
Oct-09-24 08:30AM
Oct-03-24 08:30AM
Sep-12-24 04:15PM
Jul-30-24 08:00AM
Jul-23-24 08:00AM
08:30AM Loading…
Jul-02-24 08:30AM
May-16-24 11:53AM
Mar-14-24 08:30AM
Feb-26-24 07:00AM
Dec-04-23 09:00AM
Nov-28-23 09:00AM
Aug-14-23 04:29PM
Aug-10-23 08:46AM
Aug-07-23 09:00AM
Aug-03-23 08:00AM
Jul-31-23 08:00AM
Apr-10-23 04:30PM
Apr-05-23 01:00PM
Feb-27-23 08:30AM
Feb-23-23 07:30AM
04:30PM Loading…
Feb-22-23 04:30PM
Jan-25-23 08:45AM
Jan-17-23 08:00AM
Jan-05-23 08:30AM
Jan-04-23 08:30AM
Dec-29-22 08:30AM
Dec-23-22 08:00AM
Dec-20-22 02:11PM
Dec-16-22 09:00AM
Nov-30-22 05:00PM
Nov-21-22 08:30AM
Nov-15-22 12:37PM
08:00AM
Sep-26-22 08:30AM
Aug-22-22 08:30AM
Jul-27-22 08:30AM
Jul-21-22 08:00AM
Jul-18-22 08:30AM
Jun-22-22 04:05PM
Jun-14-22 04:15PM
May-31-22 08:30AM
May-02-22 08:00AM
Apr-29-22 06:32PM
Feb-17-22 08:30AM
Jan-31-22 08:00AM
Dec-28-21 11:00AM
Dec-15-21 08:15AM
Dec-12-21 06:06AM
Dec-10-21 05:15PM
Dec-06-21 08:15AM
Dec-01-21 02:45PM
02:26PM
Nov-22-21 08:30AM
Nov-18-21 08:15AM
Nov-03-21 12:06PM
Oct-26-21 08:30AM
Sep-30-21 08:30AM
Sep-20-21 08:00AM
Aug-30-21 08:30AM
Aug-24-21 08:30AM
Aug-19-21 09:00AM
08:10AM
Aug-02-21 08:00AM
Jul-29-21 08:00AM
Jul-28-21 08:15AM
Jul-20-21 08:00AM
Jul-12-21 09:51AM
Jul-07-21 08:00AM
Jun-28-21 08:15AM
08:00AM
Jun-10-21 09:12AM
Jun-01-21 08:00AM
May-28-21 08:00AM
May-21-21 04:45PM
Apr-20-21 08:00AM
Apr-19-21 05:00PM
Apr-14-21 08:15AM
Mar-26-21 08:30AM
Mar-25-21 08:30AM
Mar-24-21 08:30AM
Mar-08-21 01:30PM
Feb-24-21 04:00PM
Feb-19-21 09:00AM
Feb-17-21 12:00AM
Jan-11-21 08:00AM
Jan-05-21 02:50PM
Dec-03-20 11:08AM
Nov-24-20 10:00AM
Nov-23-20 08:30AM
Nov-17-20 08:00AM
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.